ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Exagen Inc

Exagen Inc (XGN)

4,20
0,00
(0,00%)
Fermé 09 Juin 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Exagen Inc (XGN) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
4,20
( - )
Prix Achat
4,17
Prix Vente
4,23
Volume échangé
-
0,00 Fourchette du Jour 0,00
2,59 Plage de 52 semaines 12,23
Cap du marché
Clôture Veille
4,20
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
US$ 409 011
Actions en circulation
24 159 839
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-4,87
Bénéfice par action (BPA)
-0,88
Chiffre d'affairess (LTM)
68,38M
Bénéfice net (LTM)
-20,17M

À propos de Exagen Inc

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, ... Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient’s blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Show more

Secteur
Healthcare
Industrie
Medical Diagnostics & Screening
Site Web
Siège social
Vista, United States
Fondé
2026
Exagen Inc est coté dans le secteur Healthcare de la NASDAQ avec le ticker XGN. Le dernier cours de clôture d'Exagen était de US$4,20. Au cours de la dernière année, les actions de Exagen ont été négociées dans une fourchette de prix de US$ 2,59 à US$ 12,23.

Exagen compte actuellement 24 159 839 actions en circulation. La capitalisation boursière d'Exagen est de US$101,47 million. Exagen a un ratio cours/bénéfice (ratio PE) de -4.87.

XGN Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-1.1-20.75471698115.35.34.193522464.56800817CS
40.215.263157894743.995.553.34726714.44848218CS
121.0432.91139240513.165.552.594075473.79060728CS
26-2.8-4077.332.594341964.25148956CS
52-3.03-41.90871369297.2312.232.593681936.26003179CS
1561.0834.61538461543.1212.231.30031752995.61868844CS
260-11.48-73.214285714315.6817.581.30031239775.93384262CS

XGN - Frequently Asked Questions (FAQ)

What is the current Exagen Inc share price?
The current share price of Exagen Inc is US$ 4,20
How many Exagen Inc shares are in issue?
Exagen Inc has 24 159 839 shares in issue
What is the market cap of Exagen Inc?
The market capitalisation of Exagen Inc is USD 101,47M
What is the 1 year trading range for Exagen Inc share price?
Exagen Inc has traded in the range of US$ 2,59 to US$ 12,23 during the past year
What is the PE ratio of Exagen Inc?
The price to earnings ratio of Exagen Inc is -4,87
What is the cash to sales ratio of Exagen Inc?
The cash to sales ratio of Exagen Inc is 1,52
What is the registered address of Exagen Inc?
The registered address for Exagen Inc is 1261 Liberty Way, Vista, California, 92081
What is the Exagen Inc website address?
The website address for Exagen Inc is www.exagen.com
Which industry sector does Exagen Inc operate in?
Exagen Inc operates in the Medical Diagnostics & Screening sector

XGN Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock